Focused On-demand Library for tRNA (guanine-N(7)-)-methyltransferase non-catalytic subunit WDR4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P57081

UPID:

WDR4_HUMAN

Alternative names:

Protein Wuho homolog; WD repeat-containing protein 4

Alternative UPACC:

P57081; A8KA58; B2RCA3; B4DNQ7; D3DSK3; Q9BVM5; Q9HCR3

Background:

The tRNA (guanine-N(7)-)-methyltransferase non-catalytic subunit WDR4, also known as Protein Wuho homolog and WD repeat-containing protein 4, plays a crucial role in the post-transcriptional modification of RNA. It is essential for the formation of N(7)-methylguanine in various RNA species, including tRNAs, mRNAs, and microRNAs. This modification is vital for stabilizing tRNA tertiary structure and protecting RNAs from decay, thereby ensuring efficient protein synthesis and cellular function.

Therapeutic significance:

WDR4's involvement in Galloway-Mowat syndrome 6 and disorders characterized by microcephaly, growth deficiency, and brain malformations highlights its critical role in neurological development and renal function. Understanding the role of WDR4 could open doors to potential therapeutic strategies for these severe conditions.